The solution lies in flexibility. Sites need to be able to work in whatever formats make sense for them, whether that’s a ...

At OCT Nordics, Karin Nordbladh recounted Alligator Bioscience’s experience of implementing the FDA’s dose optimisation ...

Updated interim results with an additional ~19 weeks of follow-up since the prior update [212Pb]VMT-α-NET continues to be well-tolerated ...

Big pharmas unveil ADC and radiopharmaceutical phase 3 wins at ESMO Big pharmas report pivotal phase 3 wins for ADCs and ...

Fenbendazole has gotten a lot of attention in recent years. It is a deworming medicine that treats infections caused by ...

Akeso CEO Xia gained experience in the US before launching her own biotech company back home in China. Now its ...

In October 2025, a partnership between Biokin-a rising star in China's innovative pharmaceutical sector-and global pharmaceutical leader BMS triggered a $250 million milestone payment. This is ...

Susan Galbraith, Ph.D., AZ’s oncology R&D chief, attributed Datroway’s strong efficacy to its ADC construct, specifically its ...

Investing.com -- Ipsen SA shares climbed more than 6% on Wednesday after the French biopharmaceutical company lifted its 2025 outlook and posted third-quarter sales that beat forecasts, driven by ...

Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...

Boehringer Ingelheim's Hernexeos has shown potential beyond its second-line indication for HER2-mutant NSCLC, as recent data from the phase 1 Beamion Lung-1 trial indicated impressive results in a ...

CStone Pharmaceuticals ( OTCPK:CSPHF) Discusses CS2009 Data Interpretation and Future Clinical Development Strategy October 20, 2025 9:00 AM EDT ...